Zestoretic: Effective Hypertension and Heart Failure Management
Zestoretic
| Product dosage: 17.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.47 | $44.00 (0%) | 🛒 Add to cart |
| 60 | $1.17 | $88.00 $70.00 (20%) | 🛒 Add to cart |
| 90 | $1.07 | $132.00 $96.00 (27%) | 🛒 Add to cart |
| 120 | $1.01 | $176.00 $121.00 (31%) | 🛒 Add to cart |
| 180 | $0.96 | $264.00 $172.00 (35%) | 🛒 Add to cart |
| 270 | $0.92 | $396.00 $249.00 (37%) | 🛒 Add to cart |
| 360 | $0.91
Best per pill | $528.00 $326.00 (38%) | 🛒 Add to cart |
Synonyms | |||
Zestoretic is a fixed-dose combination antihypertensive medication containing lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. This dual-mechanism formulation is specifically designed for patients requiring multiple antihypertensive agents to achieve optimal blood pressure control. It offers the convenience of combined therapy in a single tablet, potentially improving medication adherence while effectively targeting two distinct pathways in the renin-angiotensin-aldosterone system and volume regulation. Clinical evidence supports its use in patients for whom monotherapy has proven insufficient to reach target blood pressure goals.
Features
- Contains lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) in fixed-dose combinations
- Available in multiple strength options: 10/12.5 mg, 20/12.5 mg, and 20/25 mg (lisinopril/hydrochlorothiazide)
- Once-daily oral dosing regimen
- Standard tablet formulation for easy administration
- Manufactured under strict pharmaceutical quality control standards
- Requires prescription and regular medical supervision
Benefits
- Provides synergistic blood pressure lowering through dual mechanisms of action
- Reduces cardiovascular morbidity and mortality in hypertensive patients
- Decreases peripheral edema and fluid overload through diuretic action
- Offers simplified dosing regimen compared to separate medications
- May improve medication adherence through combination therapy
- Demonstrates proven efficacy in difficult-to-control hypertension
Common use
Zestoretic is primarily indicated for the treatment of hypertension in patients for whom combination therapy is appropriate. It is not indicated for initial therapy of hypertension except in cases where patients present with significantly elevated blood pressure requiring immediate multi-agent control. The medication may also be used as part of a comprehensive management strategy for heart failure patients requiring afterload reduction and diuresis, though this represents an off-label use that requires careful clinical consideration and monitoring.
Dosage and direction
The dosage of Zestoretic must be individualized based on patient response and tolerability. Therapy should generally begin with the lowest available strength (10/12.5 mg) once daily. Dosage may be adjusted after 2-3 weeks of therapy based on blood pressure response. The maximum recommended daily dose is 80 mg lisinopril and 50 mg hydrochlorothiazide. Tablets should be taken orally, with or without food, at approximately the same time each day. Dose titration should consider the individual components’ effects, particularly regarding renal function and electrolyte balance.
Precautions
Patients should be monitored regularly for blood pressure response, renal function, and electrolyte levels, particularly potassium, sodium, and magnesium. Caution is advised in patients with impaired renal function, as dosage adjustment may be necessary. Hepatic function should be monitored in patients with pre-existing liver disease. Patients should be advised about potential dizziness, especially during initial therapy or dosage adjustments. Adequate hydration should be maintained, though excessive fluid intake should be avoided. Photosensitivity reactions may occur due to the hydrochlorothiazide component.
Contraindications
Zestoretic is contraindicated in patients with known hypersensitivity to ACE inhibitors, sulfonamide-derived drugs, or any component of the formulation. It must not be used in patients with history of angioedema related to previous ACE inhibitor therapy. Additional contraindications include anuria, significant renal impairment, and concomitant use with aliskiren in patients with diabetes. The medication is contraindicated during pregnancy, particularly in the second and third trimesters, due to potential fetal harm.
Possible side effect
Common adverse reactions may include dizziness (6.5%), headache (5.2%), cough (3.9%), fatigue (3.0%), and orthostatic effects (2.1%). Less frequent but potentially serious side effects include hypotension, hyperkalemia, hyponatremia, impaired renal function, and pancreatitis. The hydrochlorothiazide component may cause photosensitivity, gout, and glucose intolerance. ACE inhibitor-related side effects may include angioedema (0.1-0.2% of patients) and taste disturbance. Laboratory abnormalities may include increased BUN and creatinine, hyperuricemia, and electrolyte imbalances.
Drug interaction
Zestoretic may interact with multiple medication classes. Concomitant use with other antihypertensives may potentiate blood pressure lowering effects. NSAIDs may reduce the antihypertensive efficacy and increase renal impairment risk. Potassium-sparing diuretics or potassium supplements may increase hyperkalemia risk. Lithium levels may increase with concomitant use. The hypoglycemic effect of insulin and oral antidiabetic agents may be enhanced. Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension. Colestipol and cholestyramine may reduce hydrochlorothiazide absorption.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistent daily administration is important for maintaining stable blood pressure control. Patients should be educated about the importance of adherence while understanding the appropriate management of missed doses to avoid potential hypotension from double dosing.
Overdose
Overdose may manifest as hypotension, electrolyte disturbances, and renal impairment. Primary manifestations would be expected to reflect the effects of the individual components: severe hypotension from lisinopril and dehydration/electrolyte abnormalities from hydrochlorothiazide. Management should include supportive measures with volume expansion with normal saline for hypotension. Gastric lavage may be considered if ingestion was recent. Hemodialysis may be effective for removing lisinopril. Serum electrolytes and creatinine should be monitored closely, and symptomatic treatment instituted for specific abnormalities.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Tablets should be kept in their original container with the desiccant provided to maintain stability. Do not transfer to other containers that may not provide adequate protection from moisture and light.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Zestoretic is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual patient responses may vary, and treatment decisions should be based on comprehensive medical evaluation. Patients should consult their healthcare provider for personalized medical advice and report any adverse reactions promptly. The complete prescribing information should be reviewed before initiating therapy.
Reviews
Clinical studies demonstrate that Zestoretic provides effective blood pressure control in approximately 70-80% of patients who have responded inadequately to monotherapy. In the multicenter, double-blind trials, the combination therapy showed significantly greater reduction in both systolic and diastolic blood pressure compared to either component alone. Patient satisfaction surveys indicate improved adherence rates with fixed-dose combination therapy compared to free combinations. Long-term observational studies suggest maintained efficacy over 12-24 months of treatment with appropriate dose adjustments. Healthcare providers report the combination therapy as valuable for patients requiring multiple antihpertensive agents.